Healthcare Services

Global Axial Spondyloarthritis Market (2026–2030): Strategic Insights

April 17, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Axial Spondyloarthritis (axSpA) Market Over The 2026–2030 Period?

The axial spondyloarthritis (axspa) market size has shown substantial growth recently. This market is anticipated to expand from $6.56 billion in 2025 to reach $7.09 billion in 2026, driven by a compound annual growth rate (CAGR) of 8.1%. The historical expansion can be ascribed to several factors, including increasing awareness of inflammatory spinal disorders, the expanded use of TNF inhibitors, improved diagnostic imaging availability, growth in rheumatology specialty care, and increased treatment adherence initiatives.

The market for axial spondyloarthritis (axspa) is projected to experience robust expansion in the coming years, anticipated to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth over the forecast period include the increasing uptake of JAK inhibitors and IL therapies, greater investments in personalized medicine, the broadening of early screening initiatives, an expanding utilization of digital platforms for disease monitoring, and ongoing advancements in biologic drug development. Key trends expected during this period involve a heightened adoption of biologic therapies, an increased deployment of targeted anti-inflammatory medications, an amplified emphasis on early diagnosis and disease surveillance, the expansion of individualized treatment strategies, and improved incorporation of digital health solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Important Drivers Are Guiding The Axial Spondyloarthritis (axSpA) Market Growth?

The axial spondyloarthritis (axSpa) market is anticipated to expand due to the rising aging population. An aging population signifies a demographic trend where a larger proportion or higher percentage of older individuals exists within a population. Effectively managing axSpA in older individuals offers numerous benefits, including enhanced joint function and mobility, better quality of life, prevention of structural damage to the spine, lower healthcare expenditures, prevention of disability, and refined treatment approaches. For instance, Age UK, a UK-registered charity, reported that in 2023, England had 11 million individuals aged over 65. This demographic is projected to grow by 10% over the next five years and by 32% by 2043, translating to an increase of 1.1 million and 3.5 million people, respectively. Furthermore, the population aged 85+, the age group most prone to requiring health and care services, is also forecast to expand rapidly, seeing an 8.2% rise in the next five years and a 62.7% increase by 2043, corresponding to 126,000 and 956,000 people. Consequently, the expanding aging population is fueling the development of the axial spondyloarthritis (axSpa) market.

How Are Different Segments Classified In The Axial Spondyloarthritis (axSpA) Market Segment Analysis?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Trends Are Influencing The Evolution Of The Axial Spondyloarthritis (axSpA) Market?

Major companies operating within the axial spondyloarthritis (axSpA) market are concentrating on developing innovative solutions, such as next-generation biologic drug therapies, to address the rising demand for effective treatments that target inflammation and enhance long-term disease control. These biologic therapies function by modulating specific immune pathways, offering a more precise approach compared to traditional anti-inflammatory drugs, which primarily manage symptoms without directly impacting underlying immune drivers. As an illustration, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is prescribed for adults suffering from active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who exhibit objective signs of inflammation, evidenced by elevated C-reactive protein. These specific European Union (EU) authorizations represent the drug’s initial global marketing licenses for axial spondyloarthritis.

Who Are The Companies Driving Activity In The Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Get The Full Axial Spondyloarthritis (axSpA) Market Report:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Region Holds The Highest Market Share In The Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Axial Spondyloarthritis (axSpA) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795